復星醫藥(02196.HK)爲多間子公司提供擔保
復星醫藥(02196.HK)公佈,其控股子公司「蘇州二葉」擬爲其控股子公司「山東二葉」,向萊商銀行申請的本金總額不超過摺合5,000萬元人民幣(下同)的債務提供最高額連帶責任保證擔保。另外,公司擬爲控股子公司「復星健康」,向招商銀行申請的本金總額不超過1億元(含等值其他幣種)的授信額度項下債務,提供最高額連帶責任保證擔保。公司亦擬爲控股子公司「復星實業」,向上海農商行申請的本金總額不超過等值3.2億元的融資額度項下債務,提供最高額連帶責任保證擔保。
連同本次擔保,截至昨日(25日),集團實際對外擔保金額按昨日匯率摺合約195.1億元,佔去年底集團經審計歸屬於上市公司股東淨資產的約52.74%。其中,集團實際爲山東二葉擔保金額爲2.5億元、爲復星健康擔保金額爲3.8億元、爲復星實業擔保金額摺合約87.9億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.